CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
调谐 CAR：调节嵌合抗原受体 (CAR) T 细胞活性以改善安全性、疗效与灵活性的最新进展
英文原题：Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility.
查看英文原题
Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
采用基因工程改造T细胞的癌症免疫疗法已成为强效个体化治疗药物，尤其在血液系统恶性肿瘤中取得了显著临床前和临床结果。异位表达的嵌合抗原受体（CAR）可重编程免疫细胞，使其靶向并清除癌细胞。然而，CAR-T 细胞疗法的成功取决于有效抗肿瘤活性与尽量减少有害副作用之间的平衡。为改善CAR-T 细胞疗效并减轻相关毒性，不同领域的科学家正合作利用最新分子细胞生物学及合成生物学工具和技术开发新一代产品。免疫疗法领域快速演进，新方法和策略不断涌现。本综合性文献综述旨在全面介绍控制CAR-T 细胞活性的最新进展，以提高安全性、疗效和灵活性。
展开英文摘要原文
Cancer immunotherapies utilizing genetically engineered T cells have emerged as powerful personalized therapeutic agents showing dramatic preclinical and clinical results, particularly in hematological malignancies. Ectopically expressed chimeric antigen receptors (CARs) reprogram immune cells to target and eliminate cancer.
However, CAR T cell therapy's success depends on the balance between effective anti-tumor activity and minimizing harmful side effects. To improve CAR T cell therapy outcomes and mitigate associated toxicities, scientists from different fields are cooperating in developing next-generation products using the latest molecular cell biology and synthetic biology tools and technologies.
The immunotherapy field is rapidly evolving, with new approaches and strategies being reported at a fast pace. This comprehensive literature review aims to provide an up-to-date overview of the latest developments in controlling CAR T cell activity for improved safety, efficacy, and flexibility.
论文信息
- 作者
- Celichowski P、Turi M、Charvátová S、Radhakrishnan D、Feizi N、Chyra Z、Šimíček M、Jelínek T
- 第一作者单位
- Department of Haematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.Czechia
- 通讯作者单位
- Department of Haematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. matous.hrdinka@fno.cz.Czechia
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Journal of translational medicine2023 Mar 15
- 原文标识
- PubMed 36922828 · DOI 10.1186/s12967-023-04041-6
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →